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Gregory L. Moneta, MD, Section EditorFifty Percent Area Reduction After Four Weeks of Treatment is a
Reliable Indicator for Healing—Analysis of a Single-Center Cohort of
704 Diabetic Patients
Coerper S, Beckert S, Kuper MA, et al. J Diabetes Complications 2009;23:
49-53.
Conclusion: Calculating wound area reduction after 4 weeks is a valid
tool to estimate the probability that a diabetic foot wound will heal. A 50%
wound area reduction after 4 weeks of therapy indicates likely healing of a
diabetic foot wound.
Summary: Subjective and wound-based parameters can be used to
document healing of diabetic foot wounds. The only objective wound-based
parameters for healing are wound size and ultimate complete wound closure.
The authors sought to investigate whether an area reduction 50% with 4
weeks of treatment was associated with long-term probability that a diabetic
foot wound would heal.
The authors treated diabetic foot wounds according to an institutional,
interdisciplinary wound care protocol. Follow-up was documented using a
wound care documentation system and data were analyzed. The probability
of healing was assessed with the Kaplan-Meier method, with results ex-
pressed as percentage of area reduction. Patients were classified as responders
to the protocol when the percentage of wound area reduction reached at
least 50% after 4 weeks of treatment, and nonresponders when the percent-
age area reduction was 50% at 4 weeks. Healing was defined as a percent-
age area reduction of 100%.
The analyses included 704 patients with a median follow-up of 71 days
(range, 2-365 days). Wound duration was 31 days (range, 1-4018 days).
Initial wound size was 1.18 cm2 (range, 0.1-99 cm2). Bone was involved in
the base of the wound in 28%, and in 64.5% both pedal pulses were not
palpable. Major amputation rate was 2.8%, and minor amputation rate was
10.2%. Overall probability of healing was 35% after 12 weeks, 41% after 16
weeks, and 73% after 1 year. There were 334 responders (47%) and 370
nonresponders (53%). Responders had a significantly higher probability of
healing compared with nonresponders (12 weeks: 52% vs 18%, P  .0001;
16 weeks: 47% vs 27%, P  .0001; 1 year: 83% vs 65%, P  .0001).
Comment: The data suggest that diabetic foot wounds more prone to
heal will exhibit a greater healing response early in the course of their
treatment. The practical point is that if the wound has not decreased by 50%
in area after 4 weeks, an alternative form of wound therapy should be
considered.
Plasma Levels of Soluble Tie2 and Vascular Endothelial Growth Factor
Distinguish Critical Limb Ischemia from Intermittent Claudication in
Patients with Peripheral Arterial Disease
Findley CM, Mitchell RG, Duscha BD, et al. J Am Coll Cardiol 2008;52:
387-93.
Conclusion: VEGF and sTie2 are increased in critical limb ischemia.
sTie2 may be a marker and a cause of critical limb ischemia.
Summary: Patients with peripheral arterial disease (PAD) are at in-
creased risk for cardiovascular mortality. Risk is higher for those patients
with critical limb ischemia (CLI) vs those with intermittent claudication
(IC). The diagnosis of IC vs CLI is, however, purely clinical. In addition,
although a lower ankle-brachial index (ABI) is also a marker for increased
cardiovascular mortality, ABI does not distinguish between CLI and IC. A
potential biomarker that can distinguish between patients with CLI and IC
may therefore be useful in risk stratification in patients with PAD.
The authors are expert in fields of angiogenesis, and it is known that
alterations in angiogenic growth factors occur in patients with vascular
disease. It is, however, unknown whether these growth factors are altered in
the subset of cardiovascular disease patients with PAD or whether these
potential alterations in growth factors can correlate with the disease severity.
In this study the authors therefore sought to determine whether factors that
regulate angiogenesis are altered in PAD and if these alternations exist,
whether they are associated with PAD severity.
Plasma was collected from 46 patients with PAD (23 with IC and 23
with CLI) and 23 healthy controls. Plasma angiopoietin-2 (Ang2), soluble
Tie2 (sTie2), vascular endothelial growth factor (VEGF), soluble VEGF
receptor 1 (sVEGFR-1), and placenta growth factor (PlGF) were measured
from the plasma samples. In vitro studies of endothelial cells were also per-
formed with recombinant VEGF to investigate effects on sTie2 production.
Concentrations of sTie2 (P .01), Ang2 (P .001), and VEGF (P
.01) were significantly greater in PAD patients compared with controls. No
differences were found in PlGF or sVEGFR-1. Plasma Ang2 was increased in
both IC and CLI patients compared with controls (P .0001). There wereno differences in levels in patients with IC and CLI. Plasma levels of sTie2
and VEGF were similar in controls and patients with IC, but were increased
in patients with CLI (P .001 vs control or IC). Increased sTie2 and VEGF
were independent of ABI or standard cardiovascular disease risk factors.
Treatment of endothelial cells with VEFG significantly increased sTie2
shedding.
Comment: It is a bit of a stretch to suggest at this time that VEGF and
sTie2 have any utility as biomarkers for the large cohort of patients with CLI.
If, however, these biomarkers could be used as a predictor of amputation risk
in patients with CLI, adjusted for wound size and ABI, that would be useful.
The only real conclusion that can come from this study is that plasma levels
of sTie2 and VEGF are increased in patients with PAD and are different in
those with a clinical diagnosis of CLI vs those with IC. What we really need
in the group of patients with CLI is a predictor of short-term amputation
risk, and the data here are not sufficient for that degree of risk stratification.
Angina Pectoris is a Stronger Indicator of Diffuse Vascular Atheroscle-
rosis than Intermittent Claudication: Framingham Study
Kannel WB, Evans JC, Piper S, et al. J Clin Epidemiol 2008;61:951-7.
Conclusion: Angina pectoris is a stronger predictor of diffuse athero-
sclerotic cardiovascular disease than intermittent claudication (IC).
Summary: IC is an accepted marker of the presence of diffuse athero-
sclerosis and conveys an increased risk for mortality, primarily from cardio-
vascular causes. Angina pectoris, another condition provoked by exertion,
however, is generally regarded only as a hallmark of impending myocardial
infarction. As an example, the Rose angina questionnaire, a tool for epide-
miologic investigation of angina, has been tested chiefly as a predictor of
coronary morbidity and mortality. In this study the authors use population-
based data from the Framingham Study between 1949 and 1990 to assess
relative predictive values of IC or angina pectoris for a cardiovascular disease
event. The data from 1949 to 1990 were used because this was a time when
few widespread therapies were in use for prevention of cardiovascular disease
events.
The prospective cohort of this study consisted of 5209men andwomen
from Framingham, Massachusetts, who were aged 28 to 62 years at the time
of enrollment from 1948 to 1951. For 36 years of follow-up they have
received biennial examinations. The incidence of development of cardiovas-
cular disease in the Framingham participants with angina pectoris or IC was
determined relative to a reference sample free of cardiovascular disease.
There were 95 cardiovascular disease events in the 186 participants with IC,
and 206 in the 413 patients with angina pectoris. Adjusting for sex, age, and
risk factors, the proportion of the IC group developing other cardiovascular
disease was 34%, and the proportion for the angina pectoris group was
43.4%. Compared with the reference sample, the IC group had a 2.73-fold
higher age and sex-adjusted 10-year hazard ratio for cardiovascular disease
(95% confidence interval [CI], 2.21-3.38). For angina pectoris, the cardio-
vascular disease hazard ratio was 3.17 (95% CI, 2.73-3.69). The standard
risk factor adjustments cardiovascular disease hazard ratios were more ele-
vated for patients with angina pectoris than for those patients with IC.
Excess cardiovascular disease was accounted for by risk factors in 34.8% of
those with IC and 9.5% of those with angina pectoris.
Comment: Angina and IC are both hallmarks of diffuse atherosclerotic
vascular disease. The data indicate that both impart a twofold to threefold
increased risk of cardiovascular disease compared with a reference group. It
is interesting that the factors increasing risk for clinical events in other
vascular territories are not a product of the shared risk factors of patients with
IC and those with angina pectoris. Coexistent risk factors only accounted for
about 35% of the cardiovascular risk for IC and 9.5% of the hazard associated
with angina pectoris. The mechanism of this somewhat unexpected obser-
vation is uncertain. It is important to note the Framingham Study has few
African Americans or other minority populations. The data presented,
therefore, cannot be generalized to the entire United States population.
General and Abdominal Adiposity and Risk of Death in Europe
Pischon T, BoeingH,Hoffmann K, et al. N Engl JMed 2008;359:2105-20.
Conclusions: Abdominal adiposity and general adiposity are both
associated with risk of death. Waist circumference and waist-to-hip ratios, in
addition to body mass index (BMI), should be used in assessing risk of death
related to adiposity.
Summary: Calculations of BMI have been used to assess the associa-
tion between adiposity and risk of death. The authors sought to determine
whether the distribution of body fat contributes to the prediction of death
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